A Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of DT2-SCT in Subjects With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.
Also called NCT06789302
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Global Institute of Stem Cell Therapy and Research
- Registry
-
NCT06789302
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06789302. Randomized; double masking; primary purpose treatment. Start 2025-12 (anticipated); primary completion 2028-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of DT2-SCT in Subjects With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- DT2-SCT intravenous infusion
- Intervention (Other)
- Placebo
- Lead sponsor
- Global Institute of Stem Cell Therapy and Research
Record details
- Record id
cardio:ct-nct06789302- Content hash
fa927f2c51fd6873cd65ba035057b4aa71a08c70104227b6cdd46324a76daba9